Research advances in drug therapy of endometriosis
Frontiers in Pharmacology · 21.06.2023 · 14
DOI: 10.3389/fphar.2023.1199010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.06.2023. Verfasst von Jianyou Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Sc…. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Sichuan Province, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Endometriosis is one of the most common benign gynecological disorders in reproductive-aged women. The major symptoms are chronic pelvic pain and infertility. Despite its profound impact on women’s health and quality of life, its pathogenesis has not been fully elucidated, it cannot be cured and the long-term use of drugs yields severe side effects and hinders fertility. This review aims to present the advances in pathogenesis and the newly reported lead compounds and drugs managing endometriosis. This paper investigated Genetic changes, estrogen-dependent inflammation induction, progesterone resistance, imbalance in proliferation and apoptosis, angiogenesis, lymphangiogenesis and neurogenesis, and tissue remodeling in its pathogenesis; and explored the pharmacological mechanisms, constitutive relationships, and application prospects of each compound in the text. To date, Resveratrol, Bay1316957, and bardoxifene were effective against lesions and pain in controlled animal studies. In clinical trials, Quinagolide showed no statistical difference with the placebo group; the results of phase II clinical trial of the IL-33 antibody have not been announced yet; clinical trial stage III of vilaprisan was suspended due to drug toxicity. Elagolix was approved for the treatment of endometriosis-related pain, but clinical studies of Elagolix for the pretreatment of patients with endometriosis to before In vitro fertilization treatment have not been fulfilled. The results of a clinical study of Linzagolix in patients with moderate to severe endometriosis-related pain have not been disclosed yet. Letrozole improved the fertility of patients with mild endometriosis. For endometriosis patients with infertility, oral GnRH antagonists and aromatase inhibitors are promising drugs, especially Elagolix and Letrozole.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Miller School of Medicine, University of Miami, Miami, FL, United States.
Förderung
- National Natural Science Foundation of China
- Department of Science and Technology of Sichuan Province
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Shi, J., Tan, X., Feng, G., Zhuo, Y., Jiang, Z., Banda, S., Wang, L., Zheng, W., Chen, L., Yu, D., & Guo, C. (2023). Research advances in drug therapy of endometriosis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1199010
Vancouver
Shi J, Tan X, Feng G, Zhuo Y, Jiang Z, Banda S, et al. Research advances in drug therapy of endometriosis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1199010
BibTeX
@article{Shi2023,
author = {Shi, Jianyou and Tan, Xin and Feng, Guimei and Zhuo, Yuan and Jiang, Zhongliang and Banda, Srikanth and Wang, Lin and Zheng, Wei and Chen, Lu and Yu, Dongke and Guo, Chun},
title = {Research advances in drug therapy of endometriosis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1199010}
}
EUVIMED